We may never know
Time for some quiet contemplation and reflection
One of the single biggest challenges we face in cancer research is what we don’t know – or the unknown unknowns.
This is especially true for companies either facing new targets or those cases where we have seen quite a few failures in the clinic despite a seemingly logical and rational target to aim at.
What gives and why don’t things always go to the clinical plan?
Here we take a look at what’s under the hood on some key IO programs and some of the scientific concepts which may have an impact on the outcomes…
To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
